In support of the non-canonical Wnt ligand Wnt5a playing an oncogenic role in prostate cancer, Wnt5a depletion in the TRAMP mouse model of neuroendocrine prostate cancer harboring an ART877A mutation suppresses tumor onset and progression [199]. This evidence concerns the gene WNT5A and prostate cancer.